阿德福韦酯联合胸腺肽α1治疗拉米夫定耐药慢性乙肝的临床研究(1)
 |
| 第1页 |
参见附件(1496KB，2页)。
[摘要] 目的：探讨阿德福韦酯联合胸腺肽α1治疗拉米夫定耐药慢性乙肝的临床疗效。方法：将本院2007年1月～2011年9月158例拉米夫定耐药慢性乙肝患者随机分为两组，单独采用阿德福韦酯(10 mg/d，连用48周)治疗的患者作为对照组78例，采用阿德福韦酯(10 mg/d，连用48周)联合胸腺肽α1(皮下注射1.6 mg/次，每周2次，连续治疗48周)治疗的患者作为观察组80例，分别检测患者各项指标并进行比较分析。结果：观察组ALT复常情况、HBV-DNA转阴情况、HBeAg转阴情况、HBe血清转换情况在治疗后24周和治疗后48周均明显好于对照组，差异有统计学意义(P<0.05)。结论：阿德福韦酯联合胸腺肽α1治疗拉米夫定耐药慢性乙肝的临床疗效显著，值得临床广泛推广。
[关键词] 阿德福韦酯；胸腺肽α1；拉米夫定；慢性乙肝
[中图分类号] R512.6+2 [文献标识码] A [文章编号] 1674-4721(2012)01(b)-064-02
Clinical study of adefovir dipivoxil combined with thymosin α1 on treatment of lamivudine-resistant chronic hepatitis B
DENG Hui
The Second People's Hospital of Chenzhou City in Hunan Province, Chenzhou 423000, China
[Abstract] Objectives: To investigate the clinical curative effect in adefovir dipivoxil combined with thymosin α1 in the treatment of lamivudine-resistant chronic hepatitis B. Methods: One huandred and fifty eight patients in our hospital from January 2007 to September 2011 with lamivudine resistance in chronic hepatitis B were randomly divided into 2 groups, used separate adefovir dipivoxil (10 mg/d, continuous treatment for 48 weeks) treatment of patients as control group of 78 cases, with adefovir dipivoxil (10 mg/d, continuous treatment for 48 weeks) combined with thymosin α1 (subcutaneous injection of 1.6 mg/time, 2 times a week, continuous treatment for 48 weeks) treatment of the patient as the observation group of 80 cases, were detected in patients with each index and comparative analysis. Results: The observation group ALT recovery, HBV-DNA negative cases, HBeAg negative cases, HBe seroconversion in patients after 24 weeks and 48 weeks treatment was significantly better than the control group, there was significant difference (P<0.05). Conclusion: Adefovir dipivoxil combined with thymosin α1 in treatment of lamivudine-resistant chronic hepatitis B has curative clinical effect, is worthy of clinical application.
[Key words] Adefovir Dipivoxil; Thymosin α1; Lamivudine; Chronic Hepatitis B
拉米夫定长期使用于慢性乙肝患者，会导致其产生一定的耐药性，影响治疗效果[1]。阿德福韦酯可以提高拉米夫定耐药慢性乙肝患者的临床疗效[2]。胸腺肽α1联合阿德福韦酯效果更好[3] ......
您现在查看是摘要介绍页，详见PDF附件(1496KB，2页)。